Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
about
Clinical pharmacology of midazolam in neonates and children: effect of disease-a reviewOntogeny of midazolam glucuronidation in preterm infants.Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers.Inter-individual variation in midazolam clearance in children.Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) modelsScaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.Population pharmacokinetic studies in pediatrics: issues in design and analysis.Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Pain management in neurocritical care.Prediction of drug clearance in children: a review of different methodologies.Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis.Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Evaluation of an extended grid method for estimation using nonparametric distributions.Randomized controlled trial of daily interruption of sedatives in critically ill children.A novel maturation function for clearance of the cytochrome P450 3A substrate midazolam from preterm neonates to adults.Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.Remifentanil and propofol for weaning of mechanically ventilated pediatric intensive care patients.A maturation model for midazolam clearance.Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology.
P2860
Q27006333-D00A208B-6A37-4B2F-931E-AAE44EF2B251Q33587843-5E3FDA92-99DF-468D-8D9E-B9DE9CD51CD2Q33861879-58E09ABA-8604-4B2A-8E8B-AA2253199682Q35301181-E175E375-46A0-4DC8-A614-E89B2DA98337Q35753588-3987BC72-85F4-4059-8728-0A559D53DD99Q36336064-F4E7925A-DB3F-4A39-A47F-98EDA8AA3137Q36341632-08C03451-3D77-4F9E-8FB2-DCC0085DA641Q36501845-2D5B0A44-2C23-4D1C-AD19-5D9ABEBAA561Q37521422-BEB71C75-F0E6-4907-9E48-38C7C3BB48B8Q37695055-9B48AFC1-6F8F-4162-B195-0BEB3C8B112EQ37872786-8B6C7E11-9401-451F-89DF-944CDBAF96D7Q38086777-529E0C52-C0B5-45B5-A338-46AA78E4FEB3Q38124745-C7879B28-C227-4E81-82B3-EE7029200BCFQ38367747-E42B7139-2141-4D34-9659-D549DD12FBCFQ38546483-9C64C14D-E34A-492A-BC2D-26FFA8984B51Q39767125-FE6C2CDC-B275-459B-B46D-3CD19F802EFCQ40772216-AC829BED-3588-404F-BCF3-CE21DF9D316FQ42578177-16FBDF01-6AA6-46C1-B5BD-680677958284Q45023390-3D2F7CF4-50E2-49F2-B88C-830BBDCB4829Q45247905-B9CB41B4-4786-4B1B-A15F-304697D9CE95Q47600971-2FD4F3BA-50C9-41ED-9F2D-9E038BECB2CDQ48320956-1486CDED-0004-43DE-A994-2B8359F08B6AQ48335810-F1DA46F9-C495-46F5-866E-5B6E3D81CA67Q48607357-C5BBF153-558D-4E35-9D6D-8612EFB894E3
P2860
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Population pharmacokinetics an ...... atric intensive care patients.
@en
type
label
Population pharmacokinetics an ...... atric intensive care patients.
@en
prefLabel
Population pharmacokinetics an ...... atric intensive care patients.
@en
P2093
P1476
Population pharmacokinetics an ...... iatric intensive care patients
@en
P2093
E van der Giesen
J N van den Anker
P304
P356
10.1097/01.CCM.0000084806.15352.DA
P407
P577
2003-07-01T00:00:00Z